atai Life Sciences (ATAI) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $430.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
November 15, 2021 6:59 AM EST-Positive topline results from COMP360s Phase 2b study-
-RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4-
-Continued progress across 11 therapeutic programs, including initiation of Perceptions Phase 2a and DemeRxs Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort-
-Launch of atai Impact, a philanthropic program to harness the power of innovative mental health approaches for social change-
-Company to host a webcast and... More
